Dr. Kramer explains that due to the drug’s anti-fibrotic mechanism, it has performed well in clinical trials, and that doctors could prescribe the medication to patients who have been diagnosed with idiopathic pulmonary fibrosis (IPF) through the relevant testing procedures and who understand that Esbriet is not a cure, but can slow down the progression of the disease. Patients also need to know about the side-effects of the drug, which include mild to moderate nausea and rashes.
The results of a Phase 3 clinical trial for Esbriet found that patients with long-term IPF benefited from the positive aspects of the therapy just as well as patients whose severity of IPF was not as pronounced. Read more about this study here.
In a separate study, it was found that long-term use of Esbriet in severe idiopathic pulmonary fibrosis patients slowed down lung function deterioration. Read more about this research here.
Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.